Elexacaftor / Ivacaftor / Tezacaftor: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and PBAC (Australia), among others, recommended or restricted elexacaftor / ivacaftor / tezacaftor, while AOTMIT (Poland) did not recommend it.
The record spans 4.9 years, opening at HAS (France) on 18 Nov 2020 and running to 16 Oct 2025.
ZIN (Netherlands) changed its position: not recommended on 29 Apr 2021, restricted by 20 Jun 2022, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 14 of 38 records date from 2023 or later.
3 distinct indication wordings are recorded for elexacaftor / ivacaftor / tezacaftor by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 38 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess elexacaftor / ivacaftor / tezacaftor, on 18 Nov 2020; SMC (Scotland) did not open a file until 24 Jul 2024 — a wide spread of 3.7 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
5 of the 9 agencies here assessed elexacaftor / ivacaftor / tezacaftor more than once, G-BA (Germany) most often at 17 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for elexacaftor / ivacaftor / tezacaftor.
The full ledger for elexacaftor / ivacaftor / tezacaftor reads 18 recommended, 10 no benefit, 5 restricted and 4 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 16 Oct 2025 | Kaftrio — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 24 Sep 2025 | Re-assessment following post-listing study results | SMR substantial · ASMR I | source |
| PHARMAC (New Zealand) | 24 Jan 2025 | Cystic fibrosis, aged 2-5 years, with F508del mutation(s) in the CFTR gene, G551D mutation or other mutation responsive … | PTAC advice: High · decision reached | source |
| AWMSG (Wales) | 24 Jul 2024 | Kaftrio tablets are indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patie… | excluded, NICE appraised | source |
| SMC (Scotland) | 24 Jul 2024 | in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 2 years to less than 6 years (granules in sachet) and 6 years and older… | accepted | source |
33 further decisions for elexacaftor / ivacaftor / tezacaftor, across 7 agencies, are not shown here. They include the most recent record on file, 16 Oct 2025 from G-BA (Germany); its outcome is in the subscriber dataset. They link to 29 further source documents.
Related molecules
- ivacaftor — same ATC class R07A — Other respiratory
- ivacaftor / lumacaftor — same ATC class R07A — Other respiratory
- ivacaftor / tezacaftor — same ATC class R07A — Other respiratory
- bevacizumab — also decided by G-BA in 2025Q4
- lisocabtagene maraleucel — also decided by G-BA in 2025Q4
- concizumab — also decided by G-BA in 2025Q4
Coverage: 38 decisions for elexacaftor / ivacaftor / tezacaftor from 9 agencies, 2020 to 2025. Data to 7 Sep 2026. ATC class R07A — Other respiratory. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.